article thumbnail

Papa’s Herb® Enters the Oregon Market Through Halo Collective

Cannabis Law Report

TORONTO , July 19, 2021 /CNW/ – Halo Collective Inc. (“Halo” or the “Company”) (NEO: HALO) (OTCQX: HCANF) (Germany: A9KN), a vertically integrated cannabis company, announced today that it has entered into a brand licensing arrangement (the “Licensing Agreement”) with Brezwald Corp.

article thumbnail

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Veriheal

Unlike “pharmaceutical CBD”—which contains zero traces of the psychoactive compound THC (tetrahydrocannabinol) and has been FDA-approved to treat Dravet syndrome and Lennox-Gastaut syndrome —artisanal CBD is non-mechanized and usually contains variable amounts of CBD and THC. It goes by the name of “artisanal CBD.” .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Canopy Growth Divests Pharmaceutical C3 Cannabinoid Compound Company

Cannabis Law Report

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

article thumbnail

Three Major Australian Medical Cannabis Companies Fined By The TGA “over claims prescriptions could treat conditions such as cancer and epilepsy”

Cannabis Law Report

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

article thumbnail

GW Pharmaceuticals Wins the Queens Prize for Innovation

SpeedWeed

The British cannabis pharmaceutical company takes home an award that demonstrates how important cannabis has been to the British economy for over 20 years—but also how much it so far has been reserved, as an industry, and as a drug, for the elite. GW Pharmaceuticals was just awarded a so-called “ Queen’s Prize for Innovation.” .

article thumbnail

States That Restrict MMJ Access Are Interfering With Patients’ Rights, Study Shows

Veriheal

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. Many patients take MMJ for more reasons than one.

Access 98